TY - JOUR
T1 - Challenges to improved therapeutics for metastatic castrate resistant prostate cancer
T2 - From recent successes and failures
AU - Huang, Xuan
AU - Chau, Cindy H.
AU - Figg, William D.
N1 - Funding Information:
This work was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health. This is a US Government work. There are no restrictions on its use. The views expressed within this paper do not necessarily reflect those of the US Government.
PY - 2012
Y1 - 2012
N2 - Men with metastatic castration-resistant prostate cancer (mCRPC) carry poor prognosis despite the use of docetaxel-based regimens which has modest survival benefit shown by randomized clinical trials. Significant progress in the discovery of novel therapeutic agents has been made in the past few years. While sipuleucel-T, cabazitaxel, and abiraterone gained regulatory approval in 2010 and 2011, several highly promising candidates/regimens have failed in large scale clinical trials. Challenges remain to optimize the design and interpretation of clinical trial results and develop more effective strategies for mCRPC. In this review, we examined the positive and negative clinical trials in mCRPC in the past and discussed the various aspects of clinical trial design including selection of targets and appropriate outcome measures, biomarker development and implementation, and strategies for combination therapy.
AB - Men with metastatic castration-resistant prostate cancer (mCRPC) carry poor prognosis despite the use of docetaxel-based regimens which has modest survival benefit shown by randomized clinical trials. Significant progress in the discovery of novel therapeutic agents has been made in the past few years. While sipuleucel-T, cabazitaxel, and abiraterone gained regulatory approval in 2010 and 2011, several highly promising candidates/regimens have failed in large scale clinical trials. Challenges remain to optimize the design and interpretation of clinical trial results and develop more effective strategies for mCRPC. In this review, we examined the positive and negative clinical trials in mCRPC in the past and discussed the various aspects of clinical trial design including selection of targets and appropriate outcome measures, biomarker development and implementation, and strategies for combination therapy.
UR - http://www.scopus.com/inward/record.url?scp=84863085985&partnerID=8YFLogxK
U2 - 10.1186/1756-8722-5-35
DO - 10.1186/1756-8722-5-35
M3 - Review article
C2 - 22747660
AN - SCOPUS:84863085985
SN - 1756-8722
VL - 5
JO - Journal of Hematology and Oncology
JF - Journal of Hematology and Oncology
M1 - 35
ER -